Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frontier 1: Single and multiple-dose Mim8 (NNC0365-3769) in healthy males and males with severe haemophilia A
jRCT2031200136Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, randomised, double-blind trial of denecimig in hemophilia A (4 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events. Started Jan 2020; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2031200136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200136.